Merus N V (MRUS)

03:42 AM

Merus (NASDAQ:MRUS) Given Average Recommendation of “Buy” by Brokerages - Defense World

03:42 AM

Mar 11, 2025

Merus (NASDAQ:MRUS) Given New $70.00 Price Target at Bank of America - Defense World

Mar 11, 2025

Mar 10, 2025

Why Merus Shares Are Facing Pressure Today - TipRanks

Mar 10, 2025

Mar 07, 2025

Merus (NASDAQ:MRUS) Short Interest Down 13.5% in February - Defense World

Mar 07, 2025

Mar 06, 2025

Stifel maintains Buy on Merus stock with $93 target By Investing.com - Investing.com Australia

Mar 06, 2025

Mar 06, 2025

Stifel maintains Buy on Merus stock with $93 target - Investing.com

Mar 06, 2025

Mar 05, 2025

Merus N.V. Reports 2024 Earnings and Clinical Progress - TipRanks

Mar 05, 2025

Mar 05, 2025

Need To Know: The Consensus Just Cut Its Merus N.V. (NASDAQ:MRUS) Estimates For 2025 - Simply Wall St

Mar 05, 2025

Mar 04, 2025

Merus (NASDAQ:MRUS) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 04, 2025

Mar 03, 2025

Merus stock holds Buy rating and $85 target from H.C. Wainwright - Investing.com India

Mar 03, 2025

Mar 03, 2025

Merus stock holds Buy rating and $85 target from H.C. Wainwright By Investing.com - Investing.com South Africa

Mar 03, 2025

Mar 03, 2025

Merus’ (MRUS) Outperform Rating Reiterated at William Blair - Defense World

Mar 03, 2025

Mar 03, 2025

Needham & Company LLC Cuts Merus (NASDAQ:MRUS) Price Target to $83.00 - Defense World

Mar 03, 2025

Mar 02, 2025

Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts - Simply Wall St

Mar 02, 2025

Mar 01, 2025

Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates - MSN

Mar 01, 2025

Mar 01, 2025

Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS) - Yahoo Finance

Mar 01, 2025

Feb 28, 2025

Merus (NASDAQ:MRUS) Posts Quarterly Earnings Results, Beats Estimates By $0.48 EPS - MarketBeat

Feb 28, 2025

Feb 28, 2025

BMO Capital lifts Merus stock target to $96, maintains Outperform By Investing.com - Investing.com South Africa

Feb 28, 2025

Feb 28, 2025

BMO Capital lifts Merus stock target to $96, maintains Outperform - Investing.com

Feb 28, 2025

Feb 28, 2025

Merus Shares Soar Amid Breakthrough Therapy Hopes - TipRanks

Feb 28, 2025

Feb 28, 2025

Merus NV reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 28, 2025

Feb 27, 2025

Merus N.V. Updates on Petosemtamab Trials and Financial Outlook for 2025 and Beyond - Nasdaq

Feb 27, 2025

Feb 27, 2025

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update - GlobeNewswire

Feb 27, 2025

Feb 27, 2025

Merus Secures FDA Approval for Cancer Drug With $724M War Chest to Fund Operations Through 2028 - StockTitan

Feb 27, 2025

Feb 27, 2025

Merus N.V. SEC 10-K Report - TradingView

Feb 27, 2025

Feb 27, 2025

Merus N.V. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025

Feb 27, 2025

Investor Network: Merus N.V. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025

Feb 27, 2025

State of New Jersey Common Pension Fund D Buys 10,842 Shares of Merus (NASDAQ:MRUS) - MarketBeat

Feb 27, 2025

Feb 25, 2025

Merus to Present at Upcoming Investor Conferences - GlobeNewswire

Feb 25, 2025

Feb 25, 2025

Clinical-Stage Oncology Innovator Merus Schedules Two Major Investor Presentations - StockTitan

Feb 25, 2025

Feb 22, 2025

Merus (MRUS) to Release Quarterly Earnings on Wednesday - MarketBeat

Feb 22, 2025

Feb 20, 2025

Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - MSN

Feb 20, 2025

Feb 20, 2025

TimesSquare Capital Management LLC Purchases 58,760 Shares of Merus (NASDAQ:MRUS) - MarketBeat

Feb 20, 2025

Feb 19, 2025

Merus Stock Soars on Cancer Treatment Breakthrough - TipRanks

Feb 19, 2025

Feb 19, 2025

La FDA américaine a accordé le statut de thérapie innovante au pétosemtamab dans le carcinome épidermoïde de la tête et du cou positif PD-L1 positif en 1re ligne - GlobeNewswire Inc.

Feb 19, 2025

Feb 18, 2025

Merus Shares Are Up Today: What's Going On?Merus (NASDAQ:MRUS) - Benzinga

Feb 18, 2025

Feb 18, 2025

Merus Stock Surges on Breakthrough Therapy News - TipRanks

Feb 18, 2025

Feb 18, 2025

Merus Says US FDA Grants Breakthrough Therapy Designation to Petosemtamab -February 18, 2025 at 09:00 am EST - Marketscreener.com

Feb 18, 2025

Feb 18, 2025

Objective long/short (MRUS) Report - Stock Traders Daily

Feb 18, 2025

Feb 18, 2025

Petosemtamab granted Breakthrough Therapy designation by - GlobeNewswire

Feb 18, 2025

Feb 18, 2025

Revolutionary Cancer Treatment: 67% Response Rate Earns FDA Breakthrough Status for Head & Neck Cancer Drug - StockTitan

Feb 18, 2025

Feb 18, 2025

Merus N.V.'s SWOT analysis: biotech firm's stock poised for growth amid clinical trials - Investing.com India

Feb 18, 2025

Feb 17, 2025

Merus (NASDAQ:MRUS) Now Covered by Analysts at Piper Sandler - MarketBeat

Feb 17, 2025

Feb 16, 2025

BMO Capital Maintains Merus N.V. (MRUS) Outperform Recommendation - MSN

Feb 16, 2025

Feb 16, 2025

Guggenheim Reaffirms Buy Rating for Merus (NASDAQ:MRUS) - MarketBeat

Feb 16, 2025

Feb 16, 2025

Merus (NASDAQ:MRUS) Receives Average Rating of “Buy” from Analysts - Defense World

Feb 16, 2025